NEPHROS INC
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Arrangements
During the three months ended March 31, 2026, none of our directors or officers adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K.
Annual Meeting of Stockholders
The Company’s Board of Directors has not yet determined the date or time of the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). The Company intends to announce the date, time and location of the 2026 Annual Meeting through a press release and/or the filing of proxy materials with the SEC once such information has been determined.
The date of the 2026 Annual Meeting will likely be more than 30 days following the anniversary of the 2025 Annual Meeting of the Stockholders held on June 16, 2025 (the “2025 Annual Meeting”). Because the date of the 2026 Annual Meeting has not yet been established, assuming the meeting will be more than 30 days after the anniversary of the 2025 Annual Meeting, the updated deadlines for stockholder proposals or director nominations pursuant to Rule 14a-8 under the Securities Exchange Act of 1934 and the Company’s bylaws have not yet been determined. Once the Company announces the date of the 2026 Annual Meeting, stockholders will be notified of the applicable deadlines for submission of stockholder proposals and director nominations in accordance with applicable SEC rules and the Company’s governing documents.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.